Table 1

Effect of Rps6 hemizygosity and Trp53 on blood counts and eADA activity*

NonmutantRps6lox/+; Tg.MxCre/+Rps6lox/+; Tg.MxCre/+; Trp53ko/+Rps6lox/+; Tg.MxCre/+; Trp53ko/ko
No. of animals 17 20 12 
WBC, × 103/μL 7.58 ± 0.47 4.47 ± 0.35a 4.12 ± 0.53 6.39 ± 0.75b, NS 
RBC, × 106/μL 9.72 ± 0.13 5.85 ± 0.19a 7.03 ± 0.11a§ 9.12 ± 0.83a, NS 
MCV, fL 47.0 ± 0.4 59.8 ± 0.7a 55.7 ± 0.7a§ 48.3 ± 2.2a, NS 
Platelet count, × 103/μL 930 ± 17 1490 ± 89a 1181 ± 65b§ 911 ± 89b, NS 
No. of animals 
eADA, IU/g hemoglobin 1.06 ± 0.11 2.54 ± 0.45c 2.09 ± 0.15 1.13 ± 0.19c, NS 
NonmutantRps6lox/+; Tg.MxCre/+Rps6lox/+; Tg.MxCre/+; Trp53ko/+Rps6lox/+; Tg.MxCre/+; Trp53ko/ko
No. of animals 17 20 12 
WBC, × 103/μL 7.58 ± 0.47 4.47 ± 0.35a 4.12 ± 0.53 6.39 ± 0.75b, NS 
RBC, × 106/μL 9.72 ± 0.13 5.85 ± 0.19a 7.03 ± 0.11a§ 9.12 ± 0.83a, NS 
MCV, fL 47.0 ± 0.4 59.8 ± 0.7a 55.7 ± 0.7a§ 48.3 ± 2.2a, NS 
Platelet count, × 103/μL 930 ± 17 1490 ± 89a 1181 ± 65b§ 911 ± 89b, NS 
No. of animals 
eADA, IU/g hemoglobin 1.06 ± 0.11 2.54 ± 0.45c 2.09 ± 0.15 1.13 ± 0.19c, NS 

eADA indicates erythrocyte adenosine deaminase activity; MCV, mean corpuscular volume; NS, not significant; polyI:C, polyinosinic:polycytidylic acid; RBC, red blood cell count; and WBC, white blood cell count.

*

Blood counts were evaluated 16 weeks after treatment with polyI:C compound. Blood counts given as mean ± SEM with P values based on multiple regression where sex and genotype are factors. A subset of animals was evaluated for eADA activity and values are mean ± SEM with P values based on a 2-tailed Student t test, aP < .001, bP < .01, cP < .05.

+/+ or Rps6lox/+.

Nonmutant vs Rps6lox/+;Tg.MxCre/+.

§

Rps6lox/+;Tg.MxCre/+ vs Rps6lox/+;Tg.MxCre/+;Trp53ko/+.

Rps6lox/+;Tg.MxCre/+ vs Rps6lox/+;Tg.MxCre/+;Trp53ko/ko.

Nonmutant vs Rps6lox/+; Tg.MxCre/+;Trp53ko/ko.

or Create an Account

Close Modal
Close Modal